Table 1.
Baseline Characteristics
| Characteristics | Dosage Groups | P Valuea | |||
|---|---|---|---|---|---|
| 3 (n = 15) | 2 (n = 14) | 1 (n = 15) | 0 (n = 15) | ||
| Age at recruitment, median (IQR), y | 18.0 (17.0–18.0) | 16.0 (16.0–17.8) | 17.0 (17.0–17.5) | 18.0 (17.0–19.0) | .021 |
| Age at first dose of 4vHPV, median (IQR) | 12.0 (11.0–12.0) | 9.8 (10.0–11.0) | 9.0 (11.0–11.0) | NA | .001 |
| Time between: | |||||
| Dose 1 and 2, median (IQR), mo | 1.0 (1.0–6.0) | 6.0 (1.0–11.0) | NA | NA | .008 |
| Dose 1 and 3, median (IQR), mo | 6.0 (6.0–8.0) | NA | NA | NA | NA |
| Time since last dose of 4vHPV, median (IQR), y | 5.8 (5.7–5.8) | 5.8 (5.4–6.3) | 6.3 (6.3–6.3) | NA | <.0001 |
| Height, median (IQR), cm | 162.0 (145.0–168.0) | 158.5 (153.8–162.0) | 162.0 (154.0–169.0) | 161.0 (130.0–170.0) | .587 |
| BMI, median (IQR), kg/m2 | 25.1 (17.3–29.0) | 25.4 (21.2–27.1) | 23.4 (19.2–25.7) | 24.4 (22.1–28.9) | .763 |
| Ethnicity, No. (%) | |||||
| iTaukei | 7 (47) | 7 (50) | 7 (47) | 7 (47) | 0.997 |
| Fijians of Indian descent | 8 (53) | 7 (50) | 8 (53) | 8 (53) | |
| Participant’s education at time of enrollment, No. (%) | 0.149 | ||||
| No schooling | 1 (7) | 1 (7) | 1 (7) | 3 (20) | |
| Secondary school | 9 (60) | 12 (86) | 13 (86) | 7 (47) | |
| University | 5 (33) | 1 (7) | 1 (7) | 5 (33) | |
| Partner status at enrollment, No. (%) | |||||
| Boyfriend/married | 2 (13) | 1 (7) | 3 (20) | 0 (0) | 0.644 |
| No. of children | 0 | 0 | 0 | 1 | 1.000 |
| Consumption of alcohol, No. (%) | 0.455 | ||||
| Never consumed | 10 (67) | 8 (57) | 10 (67) | 8 (53) | |
| Currently < 1 alcoholic drink per wk | 2 (13) | 6 (43) | 3 (20) | 7 (47) | |
| Currently ≥1 alcoholic drinks per wk | 3 (20) | 0 (0) | 2 (13) | 0 (0) | |
| Consumption of kava, No. (%) | 0.191 | ||||
| Never consumed kava | 9 (60) | 5 (36) | 11 (74) | 9 (60) | |
| <1 kava drink per wk | 3 (20) | 8 (57) | 2 (13) | 6 (40) | |
| ≥1 kava drinks per wk | 3 (20) | 1 (7) | 2 (13) | 0 (0) | |
| Cigarette smoking, No. (%) | |||||
| Smoked ≥100 cigarettes in a lifetime | 2 (13) | 0 (0) | 1 (7) | 2 (13) | 0.864 |
| Seropositivity to HPV, No. (%) | |||||
| HPV 16 | 15 (100) | 14 (100) | 13 (95) | 1 (7) | |
| HPV 18 | 14 (92) | 11 (79) | 9 (60) | 0 (0) | |
aThe characteristics of the different dosage groups were compared using the 1-way analysis of variance test for continuous variables or the χ2 test for categorical variables.